MX338489B - Derivados de hidantoina utiles como inhibidores de kv3. - Google Patents

Derivados de hidantoina utiles como inhibidores de kv3.

Info

Publication number
MX338489B
MX338489B MX2013006343A MX2013006343A MX338489B MX 338489 B MX338489 B MX 338489B MX 2013006343 A MX2013006343 A MX 2013006343A MX 2013006343 A MX2013006343 A MX 2013006343A MX 338489 B MX338489 B MX 338489B
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives useful
hydantoin derivatives
hydantoin
compounds
Prior art date
Application number
MX2013006343A
Other languages
English (en)
Spanish (es)
Other versions
MX2013006343A (es
Inventor
Giuseppe Alvaro
Charles Large
Agostino Marasco
Anne Decor
Paolo Dambruoso
Simona Tommasi
Original Assignee
Autifony Therapeuticts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/fr
Priority claimed from GBGB1020607.6A external-priority patent/GB201020607D0/en
Priority claimed from GBGB1109508.0A external-priority patent/GB201109508D0/en
Priority claimed from GBGB1113757.7A external-priority patent/GB201113757D0/en
Application filed by Autifony Therapeuticts Ltd filed Critical Autifony Therapeuticts Ltd
Publication of MX2013006343A publication Critical patent/MX2013006343A/es
Publication of MX338489B publication Critical patent/MX338489B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013006343A 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3. MX338489B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2010/068946 WO2011069951A1 (fr) 2009-12-11 2010-12-06 Dérivés d'imidazolidinedione
GBGB1020607.6A GB201020607D0 (en) 2010-12-06 2010-12-06 Novel compounds
GBGB1109508.0A GB201109508D0 (en) 2011-06-07 2011-06-07 Novel compounds
GBGB1113757.7A GB201113757D0 (en) 2011-08-10 2011-08-10 Novel compounds
PCT/GB2011/052414 WO2012076877A1 (fr) 2010-12-06 2011-12-06 Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3

Publications (2)

Publication Number Publication Date
MX2013006343A MX2013006343A (es) 2013-09-13
MX338489B true MX338489B (es) 2016-04-18

Family

ID=45464001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006343A MX338489B (es) 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3.

Country Status (18)

Country Link
US (13) US9346790B2 (fr)
EP (1) EP2649066B1 (fr)
JP (2) JP5913357B2 (fr)
KR (1) KR101862375B1 (fr)
CN (1) CN103328467B (fr)
AU (1) AU2011340258C1 (fr)
BR (1) BR112013013914B1 (fr)
CA (1) CA2817205C (fr)
DK (1) DK2649066T3 (fr)
EA (2) EA023768B1 (fr)
ES (1) ES2560304T3 (fr)
HK (1) HK1190395A1 (fr)
IL (3) IL226256A0 (fr)
MX (1) MX338489B (fr)
PL (1) PL2649066T3 (fr)
SG (2) SG190203A1 (fr)
WO (1) WO2012076877A1 (fr)
ZA (1) ZA201403529B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2509961T3 (en) * 2009-12-11 2016-05-17 Autifony Therapeutics Ltd Imidazolidinedione derivatives
EP2649066B1 (fr) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
JP6008953B2 (ja) 2011-06-07 2016-10-19 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
CN103974944B (zh) * 2011-12-06 2016-11-02 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
CN104334548A (zh) * 2012-05-22 2015-02-04 奥蒂福尼疗法有限公司 作为kv3抑制剂的乙内酰脲衍生物
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013182851A1 (fr) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxie ou traitement de maladies dans lesquelles un modulateur des canaux kv3.3 est requis
EP3092234B1 (fr) * 2013-12-20 2018-02-14 Gilead Sciences, Inc. Composés hétérocycliques annelées comme modulateurs des canaux ioniques.
PL3094631T3 (pl) 2014-01-16 2019-07-31 Fmc Corporation Pochodne pirymidynyloksy-benzenu jako środki chwastobójcze
WO2015140326A1 (fr) * 2014-03-21 2015-09-24 Biotage Ab Procédé et appareil d'équilibrage d'une colonne de chromatographie à garnissage
CN103980205B (zh) * 2014-06-05 2016-01-20 武汉格罗宁根医药科技有限公司 N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用
TW202400564A (zh) 2015-06-05 2024-01-01 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (fr) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Modulateurs d'hydantoïne de canaux kv3
US11427549B2 (en) 2017-05-02 2022-08-30 Fmc Corporation Pyrimidinyloxy benzo-fused compounds as herbicides
WO2018220762A1 (fr) 2017-05-31 2018-12-06 大塚製薬株式会社 Composé de pyrimidine
CN107556262B (zh) * 2017-08-14 2020-05-22 四川大学 一种2-取代基芳并噁唑的制备方法
WO2020009694A1 (fr) 2018-07-03 2020-01-09 Cummins Emission Solutions Inc. Réacteur de décomposition de mélange de corps
KR20210076081A (ko) * 2018-10-16 2021-06-23 오티포니 세라피틱스 리미티드 신규한 화합물
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
AU2019296526A1 (en) * 2019-03-25 2021-09-16 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof
JP2023523501A (ja) 2020-02-06 2023-06-06 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３モジュレーター
US11638606B2 (en) 2020-04-15 2023-05-02 Bard Peripheral Vascular, Inc. Bipolar electrosurgical pleura sealing device, system, and method of operating same
EP3901152A1 (fr) 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques pour le traitment des maladies cognitives
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
CA3226856A1 (fr) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Modulateurs des canaux potassiques
KR20230084419A (ko) * 2021-12-03 2023-06-13 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
WO2024121552A1 (fr) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Composés pour le traitement de troubles du système nerveux central

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474170A (en) * 1964-01-23 1969-10-21 Fmc Corp Pesticidal carbamates of dihydrobenzofuranols
US4143055A (en) * 1978-03-27 1979-03-06 Gruppo Lepetit S.P.A. 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) * 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
CA2007830A1 (fr) * 1989-01-18 1990-07-18 Shuji Ozawa 3,3-dimethyl-2,3-dihydrobenzofurane-5-sulfonate de perfluoromethyle; methode de preparation et herbicides renfermant ce type de compose
WO1991004027A1 (fr) 1989-09-15 1991-04-04 Pfizer Inc. Nouveaux derives de n-aryle de n-heteroarylamide et d'uree en tant qu'inhibiteurs d'acyl coenzyme a: cholesterol acyl transferase
JPH03153606A (ja) * 1989-11-10 1991-07-01 Mitsui Petrochem Ind Ltd 除草剤組成物
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
MX9708802A (es) 1995-05-17 1998-02-28 Du Pont Amidas ciclicas fungicidas.
WO1996036229A1 (fr) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Amides cycliques fongicides
MX9710259A (es) 1995-06-20 1998-03-29 Du Pont Amidas ciclicas fungicidas y artropodicidas.
CN1231663A (zh) 1996-08-01 1999-10-13 纳幕尔杜邦公司 杀节肢动物剂和杀真菌剂环酰胺
CZ184599A3 (cs) 1996-11-26 1999-09-15 E. I. Du Pont De Nemours And Company Methylem substituované fungicidy a artropodicidy
WO1998023155A1 (fr) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Amides cycliques arthropodicides et fongicides
WO1998033382A1 (fr) 1997-01-30 1998-08-06 E.I. Du Pont De Nemours And Company Melanges fongicides
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
TR200200099T2 (tr) 1999-07-23 2002-06-21 Shionogi &Co., Ltd. Th2 farklılaşma inhibitörleri
CN1431896A (zh) 2000-04-04 2003-07-23 盐野义制药株式会社 含有高脂溶性药物的油性组合物
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
WO2003048134A1 (fr) 2001-12-05 2003-06-12 Japan Tobacco Inc. Compose de triazole et son utilisation therapeutique
AU2003210916B9 (en) 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
KR101332924B1 (ko) 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
HUE027894T2 (en) 2006-03-27 2016-11-28 Univ California An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EA200970700A1 (ru) 2007-04-20 2010-02-26 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
EP2252592A1 (fr) 2008-02-07 2010-11-24 Sanofi-Aventis Imidazolidine-2,4-diones substitués par un arylchalcogeno-arylalkyle, procédé de production, médicaments contenant ces composés et leur utilisation
AU2009289846B2 (en) * 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
EP2379534A1 (fr) 2008-12-22 2011-10-26 F. Hoffmann-La Roche AG Composés antiviraux hétérocycliques
DK2509961T3 (en) 2009-12-11 2016-05-17 Autifony Therapeutics Ltd Imidazolidinedione derivatives
CN102652134A (zh) 2009-12-14 2012-08-29 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
EP2649066B1 (fr) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Dérivés d'hydantoïne utiles en tant qu'inhibiteurs de kv3
JP6008953B2 (ja) 2011-06-07 2016-10-19 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2017075565A1 (fr) 2015-10-30 2017-05-04 The Johns Hopkins University Particules à poids moléculaire élevé pénétrant dans le mucus et revêtements denses

Also Published As

Publication number Publication date
EA027532B1 (ru) 2017-08-31
CA2817205C (fr) 2020-04-07
AU2011340258C1 (en) 2016-10-20
SG11201402529RA (en) 2014-06-27
DK2649066T3 (en) 2016-01-11
EA201490922A1 (ru) 2015-03-31
US11583527B2 (en) 2023-02-21
KR101862375B1 (ko) 2018-05-29
JP2016145215A (ja) 2016-08-12
JP6118927B2 (ja) 2017-04-19
IL253102A0 (en) 2017-08-31
US10265316B2 (en) 2019-04-23
US9133175B2 (en) 2015-09-15
US11541052B2 (en) 2023-01-03
CN103328467B (zh) 2016-08-10
BR112013013914B1 (pt) 2021-10-26
US20170273981A1 (en) 2017-09-28
US10555945B2 (en) 2020-02-11
US10098881B2 (en) 2018-10-16
US20130267510A1 (en) 2013-10-10
US9833452B2 (en) 2017-12-05
US20180036308A1 (en) 2018-02-08
HK1190395A1 (en) 2014-07-04
US20220054490A1 (en) 2022-02-24
US9346790B2 (en) 2016-05-24
US20160251340A1 (en) 2016-09-01
IL253104A0 (en) 2017-08-31
US10835534B2 (en) 2020-11-17
US20150336936A1 (en) 2015-11-26
ZA201403529B (en) 2020-03-25
JP5913357B2 (ja) 2016-04-27
CN103328467A (zh) 2013-09-25
BR112013013914A2 (pt) 2016-09-13
IL226256A0 (en) 2013-07-31
PL2649066T3 (pl) 2017-04-28
SG190203A1 (en) 2013-06-28
US20200360379A1 (en) 2020-11-19
US20190000849A1 (en) 2019-01-03
US20200179385A1 (en) 2020-06-11
KR20130138815A (ko) 2013-12-19
IL253102B (en) 2018-04-30
JP2013544873A (ja) 2013-12-19
WO2012076877A1 (fr) 2012-06-14
AU2011340258B2 (en) 2016-05-19
EA023768B1 (ru) 2016-07-29
US20160317537A1 (en) 2016-11-03
US11197859B2 (en) 2021-12-14
CA2817205A1 (fr) 2012-06-14
US9422272B2 (en) 2016-08-23
AU2011340258A1 (en) 2013-05-30
MX2013006343A (es) 2013-09-13
EP2649066A1 (fr) 2013-10-16
US20140323508A1 (en) 2014-10-30
US20210023084A1 (en) 2021-01-28
EP2649066B1 (fr) 2015-10-21
ES2560304T3 (es) 2016-02-18
EA201390609A1 (ru) 2014-01-30
US20190192516A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2015DN01156A (fr)
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
JO2892B1 (en) CYP inhibitors 17
MY181898A (en) Heterocyclic compounds and uses thereof
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2011000673A1 (en) Bace inhibitors
UA105911C2 (uk) Сульфонамідні похідні
EA201170832A1 (ru) Пуриновые соединения
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IN2012DN00692A (fr)
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2012004780A (es) Inhibidores de akt.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP2603216A4 (fr) Hétéroaryles et utilisations
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
CA2887539C (fr) Derives carboxamide d'azaquinazoline

Legal Events

Date Code Title Description
FG Grant or registration